Skip to main content
OpenTrials
Completed

NCT Number: NCT03313843

Study to Assess OCT: RNFL and GCL in MS Patients

The purpose of this study is to collect preliminary data on retinal nerve fiber layer and ganglion cell layer damage in multiple sclerosis (MS) patients, using optical coherence tomography (OCT). For this study the Zeiss Cirrus OCT Imaging System will be used. The same system will be used consistently for the duration of the study.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Tampa Bay Uveitis Center, New Port Richey, Florida, United States

Loading trial locations.

About this study

Hypothesis: Multiple sclerosis results in axonal degeneration which can be assessed objectively and non-invasively by serial OCT measurements of the RNFL and GCL.

This will be a prospective cross-sectional, non-interventional study; total recruitment will be 200 subjects. Recruitment will be stratified to enroll at least 50 subjects currently taking Lemtrada and 50 subjects with a documented diagnosis of ON. The study will enroll subjects primarily from practices in the Tampa Bay Area and adjacent counties. It is a planned non-interventional study; subjects will be followed by their neurologist and the study ophthalmologist and will receive standard of care. All subjects will have the ophthalmological examination and diagnostic measures, by the Principal Investigator, Dr. Grace Levy-Clarke, at Tampa Bay Uveitis Center.

Study Duration: The study duration will be 24 months, with an interim analysis at 50% recruitment status.

There are two primary aims of this longitudinal observational study:

  • To determine whether atrophy within specific retinal layers over time is associated with clinical neurological progression of MS
  • To determine whether an ON history affects the relationship described in aim # 1

Eye Exam: Subject will have an eye exam, including:

Visual Acuity Testing Color Vision Testing Automated perimetry/Peripheral Vision Testing Completing the National Eye Institute Visual Functioning Questionnaire (NEI/VFQ) Slit Lamp Examination Measurement of Intraocular Pressure (IOP) Dilated Fundus Examination (Ophthalmoscopy) Fundus Photography Optical Coherence Tomography: RNFL and Macular OCT

Neurologic Assessments: Must be performed no more than 60 days prior to screening/assessment Day 0 Ophthalmic Assessments

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 or older
  • Pregnant women will be excluded by self declaration
  • Male or female
  • A diagnosis of MS, that meets the 2010 Revised McDonald Diagnostic Criteria
  • A visual acuity of 20/400 or better in at least one eye

Exclusion criteria

  • Any ocular disease than prevents assessment of the optic nerve and macula by OCT
  • Advance glaucoma with optic nerve damage
  • Any optic neuropathy not diagnosed as ON associated with MS
  • A diagnosis of Macular Degeneration
  • Any previous ocular trauma
  • Any medical history of a cerebrovascular accident
  • Any planned ocular or systemic elective surgery during study duration
  • Any contraindication to a comprehensive dilated ophthalmic examination
  • Inability to give informed consent

Treatment and study plan

Primary outcomes

  1. Retinal Nerve Fiber Layer measurement (RNFL: peri-papillary OCT)

    Time frame: Assessed at Baseline then 6, 12, 18 and 24-month time points

    Optical Coherence Tomography (OCT) will be used to assess change in RNFL of patients with multiple sclerosis

Secondary outcomes

  1. Ganglion Cell Layer measurement (GCL: Macular OCT)

    Time frame: Assessed at Baseline then 6, 12, 18 and 24 - month time points

    Optical Coherence Tomography (OCT) will be used to assess change in GCL of patients with multiple sclerosis

Sponsors and collaborators

Lead sponsor

Tampa Bay Uveitis Center, LLC

Other

Registry information

Official study title

Prospective Cross Sectional Study To Assess The Clinical Utility of Optical Coherence Tomography to Measure Axonal Degeneration of the Optic Nerve, in a Cohort of 200 Subjects Meeting the Diagnostics Criteria of Multiple Sclerosis

Important dates

Study start
2018
Primary completion
2020
Study completion
2021
First posted
Oct 18, 2017
Registry last updated
Jun 2, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.